Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$12.18 USD

12.18
3,096,644

+2.98 (32.39%)

Updated Nov 7, 2024 11:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Athenex's NDA for Breast Cancer Drug Gets Priority Review

by Zacks Equity Research

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations

by Zacks Equity Research

Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.

Athenex (ATNX) Catches Eye: Stock Jumps 9.1%

by Zacks Equity Research

Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide

Gilead Inks Deal With Jounce to License an Oncology Candidate

by Zacks Equity Research

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Aptose Biosciences (APTO) Surges: Stock Moves 9.8% Higher

by Zacks Equity Research

Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

by Zacks Equity Research

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug

by Zacks Equity Research

The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.

Tirthankar Chakraborty headshot

This September Could Be Different: 5 Stocks to Buy

by Tirthankar Chakraborty

In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.

Sreoshi Bera headshot

Major Indexes Erase Pandemic-Led Losses: 5 Top Picks

by Sreoshi Bera

Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most

Emergent Biosolutions (EBS) Up 21.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo

by Zacks Equity Research

Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.

Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

by Zacks Equity Research

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

Alnylam's Share Price Rises YTD on Pipeline Developments

by Zacks Equity Research

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

Here's Why Hold Strategy is Apt for Acadia Healthcare Stock

by Zacks Equity Research

Acadia Healthcare (ACHC) continues to benefit from increasing demand for telehealth services, strategic buyouts and solid financial position.

Amarin (AMRN) in Focus: Stock Moves 5.5% Higher

by Zacks Equity Research

Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio

by Zacks Equity Research

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

Centene's Contract Renewal to Aid Medicaid Members in Indiana

by Zacks Equity Research

Centene's (CNC) subsidiary MHS gets a contract renewal through which it will be able to efficiently serve its Medicaid members in Indiana.

Encompass Health Forms JV to Efficiently Serve South Carolina

by Zacks Equity Research

Encompass Health (EHC) and MUSC Health intend to offer improved healthcare services in South Carolina through a joint venture.

Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study

by Zacks Equity Research

Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.

Emergent BioSolutions' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag

by Zacks Equity Research

The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.